Clinical Trial: Renal Impairment Study for Oral EC5026

U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07694544) titled 'Renal Impairment Study for Oral EC5026' on July 03.

Brief Summary: The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are:

1. To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function.

2. To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated.

Researchers will compare a sing...